TherapeuticsMD (TXMD) Trading Up 6.2%

TherapeuticsMD Inc (NASDAQ:TXMD) shares were up 6.2% during mid-day trading on Thursday . The stock traded as high as $3.58 and last traded at $3.45. Approximately 4,781,304 shares changed hands during mid-day trading, an increase of 57% from the average daily volume of 3,050,050 shares. The stock had previously closed at $3.25.

Several research analysts have recently issued reports on TXMD shares. Cantor Fitzgerald reissued a “buy” rating and issued a $27.00 price target on shares of TherapeuticsMD in a research note on Monday, January 21st. BidaskClub raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. reissued a “buy” rating and issued a $14.00 price target on shares of TherapeuticsMD in a research note on Tuesday, February 12th. ValuEngine raised TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Thursday, February 28th. Finally, Oppenheimer reissued a “buy” rating on shares of TherapeuticsMD in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. TherapeuticsMD has a consensus rating of “Hold” and an average price target of $12.75.

The company has a market cap of $832.22 million, a price-to-earnings ratio of -5.64 and a beta of 1.96. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The business had revenue of $3.95 million during the quarter, compared to analysts’ expectations of $5.96 million. During the same quarter last year, the business posted ($0.11) earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Sell-side analysts predict that TherapeuticsMD Inc will post -0.64 earnings per share for the current fiscal year.

In related news, Director Jules A. Musing sold 17,400 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $5.80, for a total transaction of $100,920.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at $29,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 22.85% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc boosted its stake in TherapeuticsMD by 9.8% during the third quarter. Vanguard Group Inc now owns 12,894,027 shares of the company’s stock valued at $84,585,000 after buying an additional 1,153,716 shares in the last quarter. Frontier Capital Management Co. LLC bought a new position in TherapeuticsMD during the fourth quarter valued at about $5,700,000. Virtu Financial LLC bought a new position in TherapeuticsMD during the first quarter valued at about $249,000. Teachers Advisors LLC boosted its stake in TherapeuticsMD by 13.3% during the third quarter. Teachers Advisors LLC now owns 353,895 shares of the company’s stock valued at $2,322,000 after buying an additional 41,607 shares in the last quarter. Finally, Dfpg Investments Inc. bought a new position in TherapeuticsMD during the fourth quarter valued at about $38,000. 80.03% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/18/therapeuticsmd-txmd-trading-up-6-2.html.

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: Why are percentage gainers important?

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.